787591-35-9

Usage

Uses

Used in Pharmaceutical Industry:
(3-[2-(MORPHOLIN-4-YL)ETHOXY]PHENYL)BORANEDIOL is used as a key intermediate in the synthesis of pharmaceuticals for its versatile reactivity and potential antitumor activity, contributing to the development of new cancer treatments.
Used in Agrochemical Industry:
(3-[2-(MORPHOLIN-4-YL)ETHOXY]PHENYL)BORANEDIOL is used as a building block in the synthesis of agrochemicals, leveraging its reactivity to create effective compounds for agricultural applications.
Used in Material Science:
(3-[2-(MORPHOLIN-4-YL)ETHOXY]PHENYL)BORANEDIOL is used as a component in the development of new materials, taking advantage of its unique properties to enhance material performance.
Used in Organic Chemistry Research:
(3-[2-(MORPHOLIN-4-YL)ETHOXY]PHENYL)BORANEDIOL is used as a catalyst in the formation of carbon-oxygen and carbon-nitrogen bonds, facilitating important reactions in organic chemistry and contributing to the advancement of chemical research.

Downstream Products

• 1139717-88-6 4-{2-[3-(6-chloropyridin-3-yloxy)phenoxy]ethyl}morpholine 

Relevant academic research and scientific papers

PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES

a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X and Y are independently NR5 or O; W and Z are independently a bond or (CH2)mCH(R7)(CH2)n; m=0-1, n=0-2; R is hydrogen or halogen; R1 and R2 are independently selected from hydrogen halogen, CF3, CN, OR8, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R3 is hydrogen, halogen, CF3, CN, OR8, SR8 or SO2R11; R4 is hydrogen, halogen, CF3, OR9, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R7 is hydrogen, C1-6 alkyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR9; R8 is hydrogen or C1-6 alkyl optionally substituted by fluorine, C1-6 alkoxy or NR9R10, R9 is hydrogen, C1-6 alkyl or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8, NR9R10 Or OCF3; R10 is hydrogen, C1-6 alkyl, C1-6 alkenyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8 or OCF3; or the groups R9 and R10 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR9, S and O; and R11 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR8 is provided. The compounds are useful in treating amyloid related diseases.

Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.